Scholar Rock Holding Corp (SRRK) is a Healthcare · Biotechnology company listed on NASDAQ. Price $46.41 (-5.32%), Market cap $6.14B, 52-week low–high $27.92 ~ $51.28.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial f
Financial statements, price targets, institutional (13F) holdings and related news for Scholar Rock Holding Corp are updated in real time on BlackAll Trade.
Scholar Rock Holding Corp trades at $46.41 (-5.32%). Real-time quotes and charts are available on BlackAll Trade.
Scholar Rock Holding Corp has a market cap of about $6.14B.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromu